Maria Luiza Fidelis da Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Luiza Fidelis da Silva has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Arquimedes Gasparotto Junior
Laboratory of Cardiovascular Pharmacology (LaFaC), Faculty of Health Sciences, Federal University of Grande Dourados (UFGD), Dourados 79804-970, MS, Brazil
5 shared publications - Annye Vitória Moraes
Laboratory of Cardiovascular Pharmacology (LaFaC), Faculty of Health Sciences, Federal University of Grande Dourados (UFGD), Dourados 79804-970, MS, Brazil
2 shared publications - Emerson Luiz Botelho Lourenço
Graduate Program in Biotechnology Applied to Agriculture, Paranaense University, Umuarama 87502-210, PR, Brazil
2 shared publications - Erdi Can Aytar
Faculty of Agriculture Department of Horticulture, Usak University, Uşak, Turkey
2 shared publications - Francislaine Aparecida dos Reis Lívero
Laboratory of Cardiometabolic Pharmacology, Departamento de Farmacologia, Federal University of Paraná, Curitiba 81530-000, PR, Brazil
2 shared publications - Gabriela Pereira da Silva
Laboratory of Cardiovascular Pharmacology (LaFaC), Faculty of Health Sciences, Federal University of Grande Dourados (UFGD), Dourados 79804-970, MS, Brazil
2 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1599
Cardioprotective Effect of Nanoencapsulated α-Amyrin in Spontaneously Hypertensive Rats with Metabolic Syndrome
Background/Objectives: Metabolic syndrome (MS) encompasses a cluster of disorders that significantly increase cardiovascular risk. While α-amyrin exhibits antioxidant and anti-inflammatory properties, its poor aqueous solubility and low oral bioavailability hinder its clinical use. This study evaluated the cardioprotective effects of α-amyrin-loaded polymeric nanocapsules (NCαA) in spontaneously hypertensive rats (SHR) with sucrose-induced MS. Methods: First, NCαA was prepared via interfacial deposition of a preformed polymer following organic solvent displacement. The formulation was characterized for particle size, zeta potential, morphology, encapsulation efficiency, and storage stability. Spontaneously hypertensive rats (SHR) received 20% sucrose for 8 weeks and were treated daily by oral gavage for 28 days with NCαA (0.1, 0.3, or 1 mg/kg), unformulated α-amyrin (1 mg/kg), hydrochlorothiazide (25 mg/kg), vehicle, or blank nanocapsules. Cardiovascular, electrocardiographic, echocardiographic, vascular, renal, and biochemical parameters were subsequently assessed. Results: Polymeric NCαA showed spherical and uniform morphology (195.10 ± 1.55 nm; PDI: 0.144; zeta potential: −52.60 mV), 85.85% encapsulation efficiency, efficient sustained release, and 90-day shelf-life stability. In vivo, MS control rats exhibited significant weight gain, hypertension, increased S-wave negative deflection depth, reduced ejection fraction, impaired acetylcholine-mediated vasodilation, depressed serum nitrite, and elevated malondialdehyde. Treatment with NCαA (particularly at 0.3 and 1 mg/kg), unlike unformulated α-amyrin, prevented excessive weight gain, normalized blood pressure, reversed electrophysiological/echocardiographic markers of cardiac overload, restored nitric oxide bioavailability, attenuated lipid peroxidation, and maintained renal hydroelectrolytic balance. Conclusions: Polymeric nanoencapsulation yielded stable nanocapsules with high sustained release, overcoming the biopharmaceutical limitations of α-amyrin. NCαA provides comprehensive cardioprotection against MS-induced damage, representing a promising multi-target strategy for cardiometabolic disorders.
- 9 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1599
Open AccessCardioprotective Effect of Nanoencapsulated α-Amyrin in Spontaneously Hypertensive Rats with Metabolic Syndrome
Background/Objectives: Metabolic syndrome (MS) encompasses a cluster of disorders that significantly increase cardiovascular risk. While α-amyrin exhibits antioxidant and anti-inflammatory properties, its poor aqueous solubility and low oral bioavailability hinder its clinical use. This study evaluated the cardioprotective effects of α-amyrin-loaded polymeric nanocapsules (NCαA) in spontaneously hypertensive rats (SHR) with sucrose-induced MS. Methods: First, NCαA was prepared via interfacial deposition of a preformed polymer following organic solvent displacement. The formulation was characterized for particle size, zeta potential, morphology, encapsulation efficiency, and storage stability. Spontaneously hypertensive rats (SHR) received 20% sucrose for 8 weeks and were treated daily by oral gavage for 28 days with NCαA (0.1, 0.3, or 1 mg/kg), unformulated α-amyrin (1 mg/kg), hydrochlorothiazide (25 mg/kg), vehicle, or blank nanocapsules. Cardiovascular, electrocardiographic, echocardiographic, vascular, renal, and biochemical parameters were subsequently assessed. Results: Polymeric NCαA showed spherical and uniform morphology (195.10 ± 1.55 nm; PDI: 0.144; zeta potential: −52.60 mV), 85.85% encapsulation efficiency, efficient sustained release, and 90-day shelf-life stability. In vivo, MS control rats exhibited significant weight gain, hypertension, increased S-wave negative deflection depth, reduced ejection fraction, impaired acetylcholine-mediated vasodilation, depressed serum nitrite, and elevated malondialdehyde. Treatment with NCαA (particularly at 0.3 and 1 mg/kg), unlike unformulated α-amyrin, prevented excessive weight gain, normalized blood pressure, reversed electrophysiological/echocardiographic markers of cardiac overload, restored nitric oxide bioavailability, attenuated lipid peroxidation, and maintained renal hydroelectrolytic balance. Conclusions: Polymeric nanoencapsulation yielded stable nanocapsules with high sustained release, overcoming the biopharmaceutical limitations of α-amyrin. NCαA provides comprehensive cardioprotection against MS-induced damage, representing a promising multi-target strategy for cardiometabolic disorders.
- Open Access
- 27 August 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1074
Green-Synthesized Gold Nanoparticles Using Pfaffia glomerata Extract Improve Maternal Hypertension and Angiogenic Markers in Pregnant Hypertensive Rats
Background: Hypertensive disorders of pregnancy present a major global health challenge. Green nanotechnology offers a strategy to enhance the stability and efficacy of bioactive natural products. This study evaluated gold nanoparticles green-synthesized with Pfaffia glomerata extract (AuNPs-PG) against gestational hypertension and fetal complications in spontaneously hypertensive rats (SHRs). Methods: P. glomerata root extract was characterized by UHPLC-MS/MS. AuNPs-PG were green-synthesized with 2 mmol/L HAuCl4 (1:5 v/v) at 40 °C and characterized by UV-Vis and DLS. Pregnant Wistar-Kyoto and SHRs were divided into naive, negative control (NC), amlodipine (5 mg/kg), and AuNPs-PG groups (0.03, 0.1, and 0.3 mg/kg) treated daily on gestational days 1–18 to evaluate maternal cardiovascular, renal, biochemical, and reproductive outcomes. Results: UHPLC-MS/MS identified 38 compounds. AuNPs-PG showed a plasmon band at 520–550 nm and 88.1 nm hydrodynamic diameter. In SHRs, 0.3 mg/kg AuNPs-PG reduced systolic blood pressure by 18.5% and mean arterial pressure by 15.4%, while mitigating vascular dysfunction by lowering phenylephrine vasoconstriction by 52.7% and boosting acetylcholine vasodilation by 239.3%. Treatment shortened QTc interval by 26.4%, normalized T-wave inversion, and restored renal excretion, increasing urinary volume by 75.0% and sodium by 94.2%. Furthermore, AuNPs-PG elevated placental growth factor by 180.9%, lowered malondialdehyde by 63.5%, and preserved placental histology. Consequently, mean fetal weight increased by 21.6%, implantation index by 50.5%, and offspring-to-mother ratio by 129.6%. Conclusions: AuNPs-PG (0.3 mg/kg) effectively mitigate maternal and fetal complications in gestational hypertension. Gold nanoparticles serve as nanocarriers, whereas surface-adsorbed phytochemicals drive the biological effects.
- 27 August 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1074
Open AccessGreen-Synthesized Gold Nanoparticles Using Pfaffia glomerata Extract Improve Maternal Hypertension and Angiogenic Markers in Pregnant Hypertensive Rats
Background: Hypertensive disorders of pregnancy present a major global health challenge. Green nanotechnology offers a strategy to enhance the stability and efficacy of bioactive natural products. This study evaluated gold nanoparticles green-synthesized with Pfaffia glomerata extract (AuNPs-PG) against gestational hypertension and fetal complications in spontaneously hypertensive rats (SHRs). Methods: P. glomerata root extract was characterized by UHPLC-MS/MS. AuNPs-PG were green-synthesized with 2 mmol/L HAuCl4 (1:5 v/v) at 40 °C and characterized by UV-Vis and DLS. Pregnant Wistar-Kyoto and SHRs were divided into naive, negative control (NC), amlodipine (5 mg/kg), and AuNPs-PG groups (0.03, 0.1, and 0.3 mg/kg) treated daily on gestational days 1–18 to evaluate maternal cardiovascular, renal, biochemical, and reproductive outcomes. Results: UHPLC-MS/MS identified 38 compounds. AuNPs-PG showed a plasmon band at 520–550 nm and 88.1 nm hydrodynamic diameter. In SHRs, 0.3 mg/kg AuNPs-PG reduced systolic blood pressure by 18.5% and mean arterial pressure by 15.4%, while mitigating vascular dysfunction by lowering phenylephrine vasoconstriction by 52.7% and boosting acetylcholine vasodilation by 239.3%. Treatment shortened QTc interval by 26.4%, normalized T-wave inversion, and restored renal excretion, increasing urinary volume by 75.0% and sodium by 94.2%. Furthermore, AuNPs-PG elevated placental growth factor by 180.9%, lowered malondialdehyde by 63.5%, and preserved placental histology. Consequently, mean fetal weight increased by 21.6%, implantation index by 50.5%, and offspring-to-mother ratio by 129.6%. Conclusions: AuNPs-PG (0.3 mg/kg) effectively mitigate maternal and fetal complications in gestational hypertension. Gold nanoparticles serve as nanocarriers, whereas surface-adsorbed phytochemicals drive the biological effects.
- Open Access
The Role of the NO/cGMP Pathway and SKCa and IKCa Channels in the Vasodilatory Effect of Apigenin 7-Glucoside
This study aimed to elucidate the vasorelaxant mechanism of action for apigenin 7-glucoside (A7G) by integrating computational and ex vivo pharmacological approaches. Molecular docking simulations were conducted to predict the binding affinities and interactions of A7G with key vascular proteins, specifically human endothelial nitric oxide synthase (eNOS-PDB ID: 1M9M), and human intermediate (IKCa-PDB ID: 9ED1) and small-conductance (SKCa-PDB ID: 6CNN) Ca2+-activated K+ channels. The vasodilatory properties of A7G were subsequently evaluated in isolated mesenteric vascular beds (MVBs) from normotensive Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR). The in silico analysis indicated that A7G possesses favorable binding affinities for the 1M9M, 9ED1, and 6CNN protein targets. Pharmacological assessments demonstrated that A7G induced a dose- and endothelium-dependent reduction in perfusion pressure in MVBs from WKY and SHR rats. The vasodilatory response to A7G was completely abrogated by perfusion with a high-potassium solution or a non-selective K+ channel blocker. Furthermore, co-administration of apamin and TRAM-34, selective inhibitors of SKCa and IKCa, respectively, also abolished the vasorelaxant effects of A7G. Collectively, these findings suggest that the vascular effects of A7G in both WKY and SHR rats involve an endothelium-dependent mechanism, likely initiated by the activation of the NO/cGMP pathway, which culminates in the opening of IKCa and SKCa channels.
Open AccessThe Role of the NO/cGMP Pathway and SKCa and IKCa Channels in the Vasodilatory Effect of Apigenin 7-Glucoside
This study aimed to elucidate the vasorelaxant mechanism of action for apigenin 7-glucoside (A7G) by integrating computational and ex vivo pharmacological approaches. Molecular docking simulations were conducted to predict the binding affinities and interactions of A7G with key vascular proteins, specifically human endothelial nitric oxide synthase (eNOS-PDB ID: 1M9M), and human intermediate (IKCa-PDB ID: 9ED1) and small-conductance (SKCa-PDB ID: 6CNN) Ca2+-activated K+ channels. The vasodilatory properties of A7G were subsequently evaluated in isolated mesenteric vascular beds (MVBs) from normotensive Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR). The in silico analysis indicated that A7G possesses favorable binding affinities for the 1M9M, 9ED1, and 6CNN protein targets. Pharmacological assessments demonstrated that A7G induced a dose- and endothelium-dependent reduction in perfusion pressure in MVBs from WKY and SHR rats. The vasodilatory response to A7G was completely abrogated by perfusion with a high-potassium solution or a non-selective K+ channel blocker. Furthermore, co-administration of apamin and TRAM-34, selective inhibitors of SKCa and IKCa, respectively, also abolished the vasorelaxant effects of A7G. Collectively, these findings suggest that the vascular effects of A7G in both WKY and SHR rats involve an endothelium-dependent mechanism, likely initiated by the activation of the NO/cGMP pathway, which culminates in the opening of IKCa and SKCa channels.
- Open Access
Vasodilator Effects of Quercetin 3-O-Malonylglucoside Are Mediated by the Activation of Endothelial Nitric Oxide Synthase and the Opening of Large-Conductance Calcium-Activated K+ Channels in the Resistance Vessels of Hypertensive Rats
We used molecular docking as a computational tool to predict the binding affinities and interactions of quercetin 3-O-malonylglucoside (Q3MG) with vascular target proteins. First, the proteins 1M9M (human endothelial nitric oxide synthase; eNOS) and 6ND0 (human large-conductance voltage- and calcium-activated K+ channels; BKCa) were downloaded from the Protein Data Bank and submitted to molecular docking studies, revealing Q3MG binding affinities for both proteins. The vascular effect of Q3MG was investigated in the perfused mesenteric vascular beds (MVBs) of spontaneously hypertensive rats. In preparations with functional endothelium, Q3MG dose-dependently reduced the perfusion pressure in MVBs. Removal of the endothelium or inhibition of the nitric oxide synthase enzyme by L-NAME blocked the vasodilation induced by Q3MG. Perfusion with a physiological solution containing high KCl or the use of a non-selective blocker of K+ channels, as well as perfusion with iberiotoxin, completely abolished the vasodilatory effects of Q3MG. The data obtained suggest that the vascular effects of Q3MG involve the activation of the NO/cGMP pathway followed by the opening of BKCa.
Open AccessVasodilator Effects of Quercetin 3-O-Malonylglucoside Are Mediated by the Activation of Endothelial Nitric Oxide Synthase and the Opening of Large-Conductance Calcium-Activated K+ Channels in the Resistance Vessels of Hypertensive Rats
We used molecular docking as a computational tool to predict the binding affinities and interactions of quercetin 3-O-malonylglucoside (Q3MG) with vascular target proteins. First, the proteins 1M9M (human endothelial nitric oxide synthase; eNOS) and 6ND0 (human large-conductance voltage- and calcium-activated K+ channels; BKCa) were downloaded from the Protein Data Bank and submitted to molecular docking studies, revealing Q3MG binding affinities for both proteins. The vascular effect of Q3MG was investigated in the perfused mesenteric vascular beds (MVBs) of spontaneously hypertensive rats. In preparations with functional endothelium, Q3MG dose-dependently reduced the perfusion pressure in MVBs. Removal of the endothelium or inhibition of the nitric oxide synthase enzyme by L-NAME blocked the vasodilation induced by Q3MG. Perfusion with a physiological solution containing high KCl or the use of a non-selective blocker of K+ channels, as well as perfusion with iberiotoxin, completely abolished the vasodilatory effects of Q3MG. The data obtained suggest that the vascular effects of Q3MG involve the activation of the NO/cGMP pathway followed by the opening of BKCa.
- Open Access
Nitric Oxide and Small and Intermediate Calcium-Activated Potassium Channels Mediate the Vasodilation Induced by Apigenin in the Resistance Vessels of Hypertensive Rats
Background: Apigenin (4′,5,7-trihydroxyflavone), a flavonoid with potential cardiovascular benefits, has unclear mechanisms of action. This study investigates its effects on vascular function in Spontaneously Hypertensive Rats (SHRs). Methods: Mesenteric vascular beds (MVBs) were isolated from SHRs and perfused with increasing doses of apigenin after pre-contraction with phenylephrine. To explore the mechanisms, different MVBs were pre-perfused with antagonists and inhibitors, including indomethacin, L-NAME, and potassium channel blockers (tetraethylammonium, a non-specific potassium channel blocker; glibenclamide, an ATP-sensitive potassium channel blocker; 4-aminopyridine, a voltage-gated potassium channel blocker; charybdotoxin a selective intermediate-conductance calcium-activated potassium channel blocker; and apamin, a selective small-conductance calcium-activated potassium channel blocker). Results: Apigenin induced a dose-dependent reduction in perfusion pressure in MVBs with intact endothelium, an effect abolished by endothelium removal. L-NAME reduced apigenin-induced vasodilation by approximately 40%. The vasodilatory effect was blocked by potassium chloride and tetraethylammonium. The inhibition of small and intermediate calcium-activated potassium channels with charybdotoxin and apamin reduced apigenin-induced vasodilation by 50%, and a combination of these blockers with L-NAME completely inhibited the effect. Conclusions: Apigenin promotes vasodilation in resistance arteries through endothelial nitric oxide and calcium-activated potassium channels. These findings suggest that apigenin could have therapeutic potential in cardiovascular disease, warranting further clinical research.
Open AccessNitric Oxide and Small and Intermediate Calcium-Activated Potassium Channels Mediate the Vasodilation Induced by Apigenin in the Resistance Vessels of Hypertensive Rats
Background: Apigenin (4′,5,7-trihydroxyflavone), a flavonoid with potential cardiovascular benefits, has unclear mechanisms of action. This study investigates its effects on vascular function in Spontaneously Hypertensive Rats (SHRs). Methods: Mesenteric vascular beds (MVBs) were isolated from SHRs and perfused with increasing doses of apigenin after pre-contraction with phenylephrine. To explore the mechanisms, different MVBs were pre-perfused with antagonists and inhibitors, including indomethacin, L-NAME, and potassium channel blockers (tetraethylammonium, a non-specific potassium channel blocker; glibenclamide, an ATP-sensitive potassium channel blocker; 4-aminopyridine, a voltage-gated potassium channel blocker; charybdotoxin a selective intermediate-conductance calcium-activated potassium channel blocker; and apamin, a selective small-conductance calcium-activated potassium channel blocker). Results: Apigenin induced a dose-dependent reduction in perfusion pressure in MVBs with intact endothelium, an effect abolished by endothelium removal. L-NAME reduced apigenin-induced vasodilation by approximately 40%. The vasodilatory effect was blocked by potassium chloride and tetraethylammonium. The inhibition of small and intermediate calcium-activated potassium channels with charybdotoxin and apamin reduced apigenin-induced vasodilation by 50%, and a combination of these blockers with L-NAME completely inhibited the effect. Conclusions: Apigenin promotes vasodilation in resistance arteries through endothelial nitric oxide and calcium-activated potassium channels. These findings suggest that apigenin could have therapeutic potential in cardiovascular disease, warranting further clinical research.